Form 4 for NVCR NovoCure Ltd
Accepted 2026-03-05 00:00:00 ET · period of report 2026-03-04 · accession 0002007766-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-05 | 2026-03-04 | NVCR | Leupin Nicolas | Former Chief Medical Off | S - Sale | $13.31 | -1,100 | 103.0K | -1% | -$14.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-03-04 | S | D | 1,100 | $13.31 | 102,979 | D | — | — | (F1) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. (F2) This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. |